Biotech company 10x Genomics (NASDAQ:TXG) reported Q4 CY2024 results , but sales fell by 10.3% year on year to $165 million.

The website you are visiting is protected and accelerated by Incapsula. Your computer may have been infected by malware and ...

At this time, I would like to welcome everyone to the 10X Genomics fourth quarter and full year 2024 earnings conference call. (Operator Instructions). I would now like to turn the conference over to ...

PLEASANTON, Calif., Feb. 18, 2025 /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial ...

Genomics (NASDAQ:TXG – Free Report) had its price objective lowered by Canaccord Genuity Group from $20.00 to $18.00 in a ...

Genomics reported a Q4 EPS loss of $(0.40), missing estimates, while revenue declined 10% year over year. Analysts lowered ...

10x Genomics (NASDAQ:TXG – Get Free Report) had its price objective reduced by Morgan Stanley from $28.00 to $26.00 in a research report issued to clients and investors on Friday,Benzinga reports.

Morgan Stanley analyst Tejas Savant maintained a Buy rating on 10x Genomics (TXG – Research Report) today and set a price target of $26.00. The ...

So, this combination makes it difficult to conclusively predict that 10x Genomics will beat the consensus EPS estimate. Does Earnings Surprise History Hold Any Clue? Analysts often consider to ...

Co-founder and CEO of 10x Genomics. Founded in 2012, 10x Genomics (NASDAQ:TXG) develops single-cell and spatial genomics solutions, enabling researchers to analyze biological systems at high ...